CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relations Site, Events and Presentations.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
Siemens brings Industrial AI to the Edge of the factory floor for secure access to…
MILPITAS, Calif., Jan. 6, 2025 /PRNewswire/ -- Amazfit, a leading global smart wearables brand owned…
MILPITAS, Calif., and LAS VEGAS, Jan. 6, 2025 /PRNewswire/ -- Zepp Clarity, the smart hearing…
MILPITAS, Calif. & LAS VEGAS--(BUSINESS WIRE)--CES -- Zepp Health Corporation (NYSE: ZEPP), a global leader…
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for…
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release…